WO2024072421A1 - Probiotic and folic acid compositions and methods of using - Google Patents
Probiotic and folic acid compositions and methods of using Download PDFInfo
- Publication number
- WO2024072421A1 WO2024072421A1 PCT/US2022/045473 US2022045473W WO2024072421A1 WO 2024072421 A1 WO2024072421 A1 WO 2024072421A1 US 2022045473 W US2022045473 W US 2022045473W WO 2024072421 A1 WO2024072421 A1 WO 2024072421A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition layer
- amount
- probiotic composition
- lactobacillus
- supplement
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 195
- 239000006041 probiotic Substances 0.000 title claims abstract description 65
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 65
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 25
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims description 35
- 239000011724 folic acid Substances 0.000 title claims description 20
- 235000019152 folic acid Nutrition 0.000 title claims description 20
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims description 14
- 229960000304 folic acid Drugs 0.000 title claims description 14
- 238000009472 formulation Methods 0.000 claims abstract description 70
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims abstract description 40
- 208000037009 Vaginitis bacterial Diseases 0.000 claims abstract description 40
- 208000024891 symptom Diseases 0.000 claims abstract description 40
- 239000013589 supplement Substances 0.000 claims abstract description 34
- 241000186660 Lactobacillus Species 0.000 claims description 90
- 235000015872 dietary supplement Nutrition 0.000 claims description 34
- 244000005700 microbiome Species 0.000 claims description 21
- 230000004888 barrier function Effects 0.000 claims description 20
- 239000004615 ingredient Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 102000010445 Lactoferrin Human genes 0.000 claims description 14
- 108010063045 Lactoferrin Proteins 0.000 claims description 14
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 14
- 229940078795 lactoferrin Drugs 0.000 claims description 14
- 235000021242 lactoferrin Nutrition 0.000 claims description 14
- 206010046935 Vaginal odour Diseases 0.000 claims description 10
- 206010056530 Vulvovaginal pruritus Diseases 0.000 claims description 10
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 8
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 8
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 8
- 210000003756 cervix mucus Anatomy 0.000 claims description 8
- 206010013990 dysuria Diseases 0.000 claims description 8
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 8
- 206010046901 vaginal discharge Diseases 0.000 claims description 8
- 229940014144 folate Drugs 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 101100114828 Drosophila melanogaster Orai gene Proteins 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 abstract description 8
- 239000010410 layer Substances 0.000 description 31
- 238000011282 treatment Methods 0.000 description 31
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 16
- 230000009467 reduction Effects 0.000 description 16
- 229940039696 lactobacillus Drugs 0.000 description 15
- 239000007787 solid Substances 0.000 description 12
- 239000000654 additive Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 210000001215 vagina Anatomy 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 8
- 230000000737 periodic effect Effects 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- -1 imidazoles Chemical class 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000736262 Microbiota Species 0.000 description 4
- 239000007894 caplet Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 229960002061 ergocalciferol Drugs 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000001892 vitamin D2 Nutrition 0.000 description 3
- 239000011653 vitamin D2 Substances 0.000 description 3
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 241001633064 Atopobium vaginae Species 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 241000207201 Gardnerella vaginalis Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000002216 antistatic agent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019143 vitamin K2 Nutrition 0.000 description 2
- 239000011728 vitamin K2 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- DIPPFEXMRDPFBK-FWTXJDITSA-N (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,5S)-5,6-dimethylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound [C]1([C@@H]2[CH2][CH2][C@@H]([C@]2([CH2][CH2][CH2]1)[CH3])[C@H]([CH3])[CH2][CH2][C@H](C)[CH]([CH3])[CH3])=[CH][CH]=[C]1[CH2][C@@H](O)[CH2][CH2][C]1=[CH2] DIPPFEXMRDPFBK-FWTXJDITSA-N 0.000 description 1
- XSSMKBYYGOUGFP-BBDGQJMTSA-N (2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid chromium Chemical compound [Cr].OC(=O)[C@@H](N)CC1=CNC=N1.OC(=O)[C@@H](N)CC1=CNC=N1.OC(=O)[C@@H](N)CC1=CNC=N1 XSSMKBYYGOUGFP-BBDGQJMTSA-N 0.000 description 1
- RMDJVOZETBHEAR-KWRPXEFJSA-N (5Z,7E)-(3S,24S)-24-ethyl-9,10-seco-5,7,10(19)-cholestatrien-3-ol Chemical compound [C]1([C@@H]2[CH2][CH2][C@@H]([C@]2([CH2][CH2][CH2]1)[CH3])[C@H]([CH3])[CH2][CH2][C@@H](CC)[CH]([CH3])[CH3])=[CH][CH]=[C]1[CH2][C@@H](O)[CH2][CH2][C]1=[CH2] RMDJVOZETBHEAR-KWRPXEFJSA-N 0.000 description 1
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- KPQZUUQMTUIKBP-UHFFFAOYSA-N 1-(2-methyl-5-nitro-1-imidazolyl)-2-propanol Chemical compound CC(O)CN1C(C)=NC=C1[N+]([O-])=O KPQZUUQMTUIKBP-UHFFFAOYSA-N 0.000 description 1
- MBSCHHMCRIMBDZ-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;nitric acid Chemical compound O[N+]([O-])=O.NC(=N)N(C)CC(O)=O MBSCHHMCRIMBDZ-UHFFFAOYSA-N 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- URQMEZRQHLCJKR-UHFFFAOYSA-N 3-Methyl-5-propyl-2-cyclohexen-1-one Chemical compound CCCC1CC(C)=CC(=O)C1 URQMEZRQHLCJKR-UHFFFAOYSA-N 0.000 description 1
- GGGCYYSTDKXIBS-UHFFFAOYSA-N 3-aminopropanoic acid;nitric acid Chemical compound O[N+]([O-])=O.NCCC(O)=O GGGCYYSTDKXIBS-UHFFFAOYSA-N 0.000 description 1
- YBJHBAHKTGYVGT-OOZYFLPDSA-N 5-[(3as,4r,6ar)-2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-OOZYFLPDSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000021537 Beetroot Nutrition 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001406909 Crateva Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241001561398 Lactobacillus jensenii Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000146029 Lindera aggregata Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- DIPPFEXMRDPFBK-UHFFFAOYSA-N Vitamin D4 Natural products C1CCC2(C)C(C(C)CCC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C DIPPFEXMRDPFBK-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000003650 acai Nutrition 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229940038481 bee pollen Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940060736 chromium polynicotinate Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- WYYQVWLEPYFFLP-UHFFFAOYSA-K chromium(3+);triacetate Chemical compound [Cr+3].CC([O-])=O.CC([O-])=O.CC([O-])=O WYYQVWLEPYFFLP-UHFFFAOYSA-K 0.000 description 1
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000020237 cranberry extract Nutrition 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 239000001771 mentha piperita Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000020956 nicotinamide riboside Nutrition 0.000 description 1
- 239000011618 nicotinamide riboside Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 description 1
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004076 secnidazole Drugs 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000004092 self-diagnosis Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- RNUCUWWMTTWKAH-JLHYYAGUSA-N ubiquinol-2 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1OC RNUCUWWMTTWKAH-JLHYYAGUSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- DIPPFEXMRDPFBK-JPWDPSJFSA-N vitamin D4 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C DIPPFEXMRDPFBK-JPWDPSJFSA-N 0.000 description 1
- RMDJVOZETBHEAR-LQYWTLTGSA-N vitamin D5 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](CC)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C RMDJVOZETBHEAR-LQYWTLTGSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
Definitions
- the vaginal microbiome plays an essential role in a woman’s health. It is a dynamic environment and experiences variations in the composition of the microbiota during menstrual cycles and as a women ages because of changes in hormonal levels.
- a healthy vaginal microbiome is dominated by Lactobacillus bacteria; generally, at least 90% of the entire vaginal microbiota comprises Lactobacilli. It is believed that maintaining a healthy Lactobacilli microbiome in the vagina can aid in maintaining a healthy pH (i.e., slightly acidic, pH of about 3.8-45, as a result of the acid-producing Lactobacilli) and causing competitive crowding, thereby preventing infection and other ailments.
- BV yeast infections and bacterial vaginosis
- BV results from replacement of Lactobacilli with anaerobic organisms, such as Gardnerella vaginalis and Atopobium vaginae among others, and results in symptoms such as vaginal discharge, vaginal odor, vaginal itching, and painful urination, all of which may cause discomfort in women.
- BV is a common condition that affects many women globally, as BV is estimated to impact up to 30% of women in the western world, and up to 50% of women in the developing world.
- Treatments for BV generally comprise small-molecules, such as imidazoles, and antibiotics, such as azithromycin, clarithromycin, or erythromycin.
- examples of BV treatments are metronidazole, clindamycin, miconazole, tinidazole, and secnidazole. While these treatments, along with other treatments such as yeast treatments, may confer relief of BV and the symptoms associated therewith, there are high rates of recurrence of BV associated with these treatments.
- Recurrence rates of BV following administration of treatments of the prior art can reach as high as about 30% within 1 month and 50% within 12 months following administration of the treatment.
- the inventors have identified a growing demand to develop formulations to treat, prevent, or ameliorate BV, yeast, or the symptoms associated therewith, while ensuring maximal patient comfort and compliance.
- the inventors have noted the relationship between the vaginal microbiome and its role in BV, yeast, or symptoms associated therewith.
- administering an oral multi-component formulation, comprising a probiotic composition of at least one Lactobacillus strain concurrently with at least one nutritional supplement provides superior, and unexpected benefits, compared to the individual components alone.
- Such a finding is novel and remains to be seen in the prior art.
- therapeutic and nutraceutical benefits can be realized, either individually, collectively, or in conjunction with other pharmaceutical agents and/or dietary supplements.
- Embodiments of the present disclosure relate to novel oral formulations comprising at least one probiotic Lactobacillus bacteria and at least one nutritional supplement and their use in the amelioration, prevention, and/or treatment of the symptoms associated with BV or yeast infections.
- FIG. 1 shows a table demonstrating results from respondents that provided responses to survey questions concerning their emotions regarding the foregoing symptoms and respondents reported improvements to their levels of frustration, worry about symptoms, embarrassment, levels of affection, and levels of intimate desire.
- Some embodiments provide a composition comprising an amount of at least one Lactobacillus species formulated as a probiotic composition.
- the Lactobacillus species can be Lactobacillus jensenii, Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus casei, Lactobacillus salivarius, Lactobacillus gasseri, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus brevis, Lactobacillus reuteri, Lactobacillus bulgaricus, Lactobacillus crispatus, Lactobacillus johnsonii, Lactobacillus helveticus, or any combination thereof.
- Some embodiments can be formulated to have varying amounts of these one or more Lactobacillus species.
- a probiotic composition can comprise a first Lactobacillus species and a second Lactobacillus species, wherein the first Lactobacillus species and the second Lactobacillus species are formulated in a ratio.
- a ratio of the first Lactobacillus species and the second Lactobacillus species can be about 4: 1
- a ratio of the first Lactobacillus species and the second Lactobacillus species can be about 1: 1.
- a ratio of the first Lactobacillus species and the second Lactobacillus species can be within the range of about 10:1 to about 1 : 10.
- a ratio of the first Lactobacillus species and the second Lactobacillus species may be about 2: 1 , about 3: 1, about 4: 1, about 5: 1, about 6:1 , about 7: 1, about 8:1, about 9: 1, about 10: 1, about 1:2, about 1 :3, about 1 :4, about 1 :5, about 1 :6, about 1 :7, about 1 :8, about 1 :9, or about 1 :10.
- a probiotic composition can comprise an amount of at least one Lactobacillus species of about 1 billion CFU to about 20 billion CFU, or any ratio in between.
- the amount of the at least one Lactobacillus species can be about 1 billion CFU to about 4 billion CFU.
- Some embodiments can comprise an amount of at least one Lactobacillus species of about 4 billion or more CFU.
- the amount of the at least one Lactobacillus species can be about 4 billion CFU to about 10 billion CFU.
- the amount of the at least one Lactobacillus species can be about 10 billion CFU to about 20 billion CFU.
- a probiotic composition can comprise an amount of a first Lactobacillus species and a second Lactobacillus species. In certain embodiments, the amount of both the first Lactobacillus species and second Lactobacillus species can be about 1 billion CFU to about 5 billion CFU. Some embodiments can comprise an amount of a first Lactobacillus species and a second Lactobacillus species of about 5 billion or more CFU. In certain embodiments, the amount of both the first Lactobacillus species and second Lactobacillus species can be about 5 billion CPU to about 10 billion CFU. In some embodiments, the amount of both the first Lactobacillus species and second Lactobacillus species can be about 10 billion CFU to about 20 billion CFU.
- the amount of the first Lactobacillus species can be about 1 billion CFU to about 5 billion CFU and second Lactobacillus species can be about 5 billion CFU to about 10 billion CFU. In some embodiments, the amount of the first Lactobacillus species can be about 1 billion CFU to about 5 billion CFU and second Lactobacillus species can be about 10 billion CFU to about 20 billion CFU. In some embodiments, the amount of the first Lactobacillus species can be about 5 billion CFU to about 10 billion CFU and second Lactobacillus species can be about 1 billion CFU to about 5 billion CFU.
- the amount of the first Lactobacillus species can be about 5 billion CFU to about 10 billion CFU and second Lactobacillus species can be about 10 billion CFU to about 20 billion CFU. In some embodiments, the amount of the first Lactobacillus species can be about 10 billion CFU to about 20 billion CFU and second Lactobacillus species can be about 1 billion CFU to about 5 billion CFU. In certain embodiments, the amount of the first Lactobacillus species can be about 10 billion CFU to about 20 billion CFU and second Lactobacillus species can be about 5 billion CFU to about 10 billion CFU.
- an oral formulation may comprise at least one probiotic Lactobacillus bacteria and at least one nutritional supplement, as described herein.
- Certain embodiments comprise a method of balancing the vaginal microbiome, the method comprising: identifying a subject with a pH level above about 4.5; administering an oral multicomponent formulation, wherein the oral multi-component formulation comprises: a probiotic composition layer, wherein the probiotic composition layer comprises an amount of at least one Lactobacillus species; a supplement composition layer, wherein the supplement composition layer comprises an amount of at least one nutritional supplement ingredient; and a middle barrier layer disposed between the probiotic composition layer and the supplement composition layer, wherein the probiotic composition layer and the supplement composition layer are positioned on opposing sides of the middle barrier layer.
- Certain embodiments comprise a method of regulating, restoring, or balancing the vaginal pH of a subject, the method comprising: identifying a subject in need thereof; administering an oral formulation of one or more formulations as set forth herein.
- the oral formulation is a multi-component formulation.
- the oral formulation comprises one or more of a probiotic composition and a nutritional supplement.
- a probiotic composition may further comprise an amount of at least one additional additive that reduces sensitivity to moisture and/or prolongs shelf-life of the probiotic composition.
- the amount of the at least one additional additive can be between about 10 mg and about 500 mg.
- the amount of the at least one additional additive in the probiotic composition may be about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, or any range or amount in between any two of the preceding values and any other ranges or amounts disclosed herein.
- the at least one additional additive may be lactoferrin.
- the additional additive may be lactoferrin
- the probiotic composition may comprise an amount of lactoferrin between about 10 mg and about 500 mg.
- the amount of lactoferrin in the probiotic composition can be about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, or any range or amount in between any two of the preceding values and any other ranges or amounts disclosed herein.
- compositions comprising at least one nutritional supplement ingredient formulated as a supplement composition.
- the at least one nutritional supplement ingredient can be an essential fatty acid, such as linolenic acid or linoleic acid, or an essential amino acid, such as tryptophan, lysine, methionine, phenylalanine, threonine, valine, leucine, isoleucine, arginine, or histidine, or any combination thereof.
- an essential fatty acid such as linolenic acid or linoleic acid
- an essential amino acid such as tryptophan, lysine, methionine, phenylalanine, threonine, valine, leucine, isoleucine, arginine, or histidine, or any combination thereof.
- the at least one nutritional supplement ingredient can be a vitamin, such as retinol (vitamin A), thiamine (vitamin Bl), riboflavin (vitamin B2), niacin (vitamin B3), pantothenic acid (vitamin B5), pyridoxine, pyridoxamine, or pyridoxal (vitamin B6), biotin (vitamin B7) or pharmaceutically acceptable salts thereof, folic acid (vitamin B9) or pharmaceutically acceptable salts thereof, cobalamin (vitamin B12), choline, ascorbic acid (vitamin C) or pharmaceutically acceptable salts thereof, ergocalciferol (vitamin D2), calciferol (vitamin D3), 22-dihydroergocalciferol (vitamin D4), sitocalciferol (vitamin D5), tocopherol (vitamin E), phylloquinone (vitamin KI), menaquinone (vitamin K2), menadione (vitamin K
- the at least one nutritional supplement ingredient can be a dietary’ mineral, such as chromium, including, chromium polynicotinate, chromium acetate, chromium histidinate, chromium nicotinate, chromium chloride, and the like, or any or any pharmaceutically acceptable salts, hydrates, solvates, or mixtures thereof, bromine, cobalt, copper, fluorine, germanium, iodine, iron, magnesium, manganese, molybdenum, potassium, selenium, silicon, zinc, calcium, phosphorous, sodium, sulfur, vanadium, or any combination thereof.
- chromium including, chromium polynicotinate, chromium acetate, chromium histidinate, chromium nicotinate, chromium chloride, and the like, or any or any pharmaceutically acceptable salts, hydrates, solvates, or mixtures thereof, bromine, cobalt, copper, fluorine
- the at least one nutritional supplement ingredient can be n-acetyl cysteine, nicotinamide riboside, resveratrol, NAD+ precursors, Coenzyme Q10, reduced Coenzyme Q10, omega-3-fatty acids, bee pollen, cabbage powder, pterostilbene, nicotinamide mononucleotide, cranberry extract, turmeric or an extract thereof, royal jelly, acai berry, beet root or an extract thereof, coral calcium, oyster shell, Gotu kola or an extract thereof.
- Gingko biloba or an extract thereof lions mane mushroom, pomegranate, hibiscus flower, strawberry powder, dandelion root, celery powder, parsley powder, peppermint leaf, cinnamon bark powder, maca root, phycocyanin or an extract thereof, pumpkin seed or an extract thereof, Crataeva nurvala or an extract thereof, Lindera aggregata or an extract thereof, citrulline nitrate, creatine nitrate, beta-alanine, beta-alanine nitrate, or any combination thereof.
- the amount of the nutritional supplemental ingredient, disclosed herein can be about 10 ⁇ g to about 1 g.
- the amount of the composition can be about 10 ⁇ g, 15 ⁇ g, 20 ⁇ g, 25 ⁇ g, 30 ⁇ g, 35 ⁇ g, 40 ⁇ g, 45 ⁇ g, 50 ⁇ g, 55 ⁇ g, 60 ⁇ g, 65 ⁇ g, 70 ⁇ g, 75 ⁇ g, 80 ⁇ g, 85 ⁇ g, 90 ⁇ g, 95 ⁇ g, 100 ⁇ g, 125 ⁇ g, 150 ⁇ g, 175 ⁇ g, 200 ⁇ g, 225 ⁇ g, 250 ⁇ g, 275 ⁇ g, 300 ⁇ g, 325 ⁇ g, 350 ⁇ g, 375 ⁇ g, 400 ⁇ g, 425 ⁇ g, 450 ⁇ g, 475 ⁇ g, 500 ⁇ g, 525 ⁇ g, 575 ⁇ g, 600 ⁇ g, 625 ⁇ g, 650 ⁇ g,
- Some embodiments can be formulated as a multi-component formulation that can comprise a nutritional supplement and/or a probiotic composition, as disclosed herein, disposed as the center layer of the formulation, a nutritional supplement composition, as disclosed herein, disposed as the outer layer of the formulation, and a middle barrier layer disposed therebetween, wherein the probiotic composition layer and the nutritional supplement composition layer are positioned on opposing sides of the middle barrier layer.
- a multi-component formulation can be formulated as a tablet, a hard capsule, a soft capsule, a plant-derived capsule, gel capsule, caplet. or the iike.
- the probiotic composition can be formulated as a solid, such as a powder, granule, amorphous solid, crystalline solid, or the like, and the nutritional supplement can be formulated as a solid, such as a powder, granule, amorphous solid, crystalline solid or the composition can be formulated as a liquid, such as an aqueous solution, an oil-based solution, an aqueous suspension, an oil suspension, an emulsion, a syrup, an elixir, or the like.
- Some embodiments can comprise a combination of the foregoing forms of formulations.
- a multi-component formulation can be formulated as a tablet, a hard capsule, a soft capsule, a plant-derived capsule, gel capsule, caplet, or the like.
- the multicomponent formulation can comprise a probiotic composition disposed as a layer, a nutritional supplement composition disposed as a layer, and a barrier layer disposed therebetween, wherein the probiotic composition layer and the supplement composition layer are positioned on opposing sides of the middle barrier layer.
- the probiotic composition can be formulated as a solid, such as a powder, a granule, particles, an amorphous solid, a crystalline solid, or the like, and the nutritional supplement can be formulated as a solid, such as a powder, granule, amorphous solid, crystalline solid or the composition can be formulated as a liquid, such as an aqueous solution, an oil-based solution, an aqueous suspension, an oil suspension, an emulsion, a syrup, an elixir, or the like.
- Some embodiments can comprise a combination of the foregoing forms of formulations.
- the middle barrier layer can be comprised of excipients that would separate the probiotic composition from the supplement composition.
- the barrier layer can be included in the formulation by art-recognized coating or layering procedures.
- the barrier layer may be comprised of pharmaceutically acceptable compounds such as, for example, sugar-, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose sodium and others, used alone or in mixtures.
- the middle barrier portion is comprised of a controlled release, delayed release, or enteric coating to control or delay the release of the inner contents of the formulation.
- the multi-component formulation includes an outer coating.
- the outer coating serves to provide an immediate release, controlled-release, delayed-release, or enteric-coating to control or delay the release of the supplement composition and probiotic composition.
- the outer coating layer (or layers) can be applied by coating or layering procedures which are well-established in the relevant arts.
- the outer coating layer can be at least one of a pharmaceutically acceptable compound selected from the group consisting of sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose sodium and combinations thereof.
- Additives including plasticizers, colorants, pigments, fillers, anti-tacking, and anti-static agents can optionally be included in the outer coating.
- the outer coating regulates release of the supplement composition and/or probiotic composition from the tablet, capsule, caplet, or the like. Controlled-release, delayed-release, and/or enteric-coating technology is well-established in the pharmaceutical and formulation arts. Compositions described herein can be formulated as sustained or slow release, designed to be released into the gastrointestinal tract of a patient at a specified rate of delivery.
- a probiotic composition, a supplement composition, a middle barrier layer, and/or an outer coating, as described herein may include one or more excipients, such as the following classes of agents: sweeteners, flavoring agents, coloring agents, coatings, preservatives, lubricants, binders, surfactants, fillers, disintegrants, suspending agents, dispersing agents, wetting agents, thickening agents.
- excipients such as the following classes of agents: sweeteners, flavoring agents, coloring agents, coatings, preservatives, lubricants, binders, surfactants, fillers, disintegrants, suspending agents, dispersing agents, wetting agents, thickening agents.
- the one or more excipients may be one or more of glycerin, hydroxypropyl methylcellulose, microcrystalline cellulose, magnesium stearate, silicon dioxide, calcium carbonate, sodium carbonate, lactose, calcium phosphate, sodium phosphate, corn starch, alginic acid, starch, gelatin, acacia, stearic acid, talc, glyceryl monostearate, glyceryl distearate, kaolin, peanut oil, liquid paraffin, olive oil, arachis oil, sesame oil, coconut oil, sucrose, saccharin, beeswax, hard paraffin, xanthan gum, cetyl alcohol, sorbitol, or any combination of the foregoing.
- the excipients that may be included in any composition, a middle layer, or a coating, as described herein, are not particularly limited.
- a multi-component formulation comprising a probiotic composition and a supplement composition can be administered to a subject to treat, ameliorate, or prevent BV or yeast infections.
- a multicomponent formulation comprising a probiotic composition and a supplement composition, as described herein can be administered to a subject to treat, ameliorate, or prevent in a subject experiencing symptoms associated with BV or yeast infections, such as vaginal odor, vaginal itching, vaginal discharge, painful urination, or any combination thereof, even if the subject does not have BV or a yeast infection.
- a multi-component formulation comprising a probiotic composition and a supplement composition, according to the disclosure, can be administered to a subject to restore or maintain healthy or optimal levels of Lactobacilli within the vaginal microbiome.
- a multi-component formulation comprising a probiotic composition and a supplement composition to prevent BV/yeast, vaginal odor, vaginal itching, vaginal discharge, painful urination, or any combination thereof, as described herein, can be administered to a subject at least once daily for a periodic cycle.
- a periodic cycle of at least once daily administration can comprise administering the formulation to a subject once a day for about 2 consecutive days to about 20 consecutive days.
- a periodic cycle of at least once daily administration can comprise administering the formulation to a subject once a day for about 15 consecutive days.
- the periodic cycle of at least once daily administration may be repeated on a monthly basis.
- a periodic cycle of at least once daily administration may comprise administering the formulation to a subject once a day for about 15 consecutive days, and the periodic cycle may be repeated monthly for at least one month consecutively, six months consecutively, twelve months consecutively, or longer.
- a dosage cycle can be one dose per month, one dose every 15 days, one dose every 10 days, one dose every 5 days, one dose ever two days, or daily dosage.
- treating, ameliorating, or preventing yeast/BV, vaginal odor, vaginal itching, vaginal discharge, painful urination, or any combination thereof may result in symptomatic improvement in a subject after about one periodic cycle, as described herein.
- a subject may observe amelioration and/or treatment of BV or symptoms associated therewith.
- a subject may be more likely to be prevented from contracting BV or experiencing a symptom associated therewith.
- yeast infections, BV or the symptoms associated therewith result from a reduction in the concentration of Lactobacilli within the vaginal microbiota. Accordingly, it is believed that by supplementing the vaginal microbiota with Lactobacilli, BV, yeast or its associated symptoms can be treated, prevented, ameliorated. It is believed that the embodiments disclosed herein maintain and/or restore concentration of Lactobacilli within the vaginal microbiome to healthy or optimum levels through multiple mechanisms.
- the at least one Lactobacillus strain effectively restores the Lactobacilli content of the vaginal microbiome by directly increasing the Lactobacilli content, and in some instances, by controlling growth of other microorganisms (non-Lactobacilli) within the vaginal flora.
- the at least one Lactobacillus strain may be Lactobacillus acidophilus, which ferments sugar to produce lactic acid and thrives in an acidic environment (pH ⁇ 5). Both the lactic acid compound and a low pH (a consequence of circulating lactic acid) may be hostile to non-Lactobacilli microorganisms, thereby increasing the relative concentration of Lactobacilli in the vaginal microbiome.
- the nutritional supplement increases the effective amount of Lactobacilli delivered to the vagina. It is also believed that the nutritional supplement increases the viability of the at least one Lactobacillus strain once in the body of a subject.
- the nutritional supplement may be folic acid or a pharmaceutically acceptable salt thereof.
- folic acid or a pharmaceutically acceptable salt thereof increases the amount (CFU count) of the Lactobacillus strain(s) once the formulation is within the body and the nutritional supplement and Lactobacillus strain(s) “mix” (they are separated in different compartments within the multi-component formulation), such that the amount (CFU count) of the Lactobacillus strain(s) is significantly higher in the presence of folic acid or a pharmaceutically acceptable salt thereof compared to the an amount (CFU count) of the Lactobacillus strain(s) that would exist were no folic acid or a pharmaceutically acceptable salt thereof present.
- This increase results in a higher “effective dose” in the formulation, and therefore a higher dose being delivered to the vagina of the individual receiving treatment.
- the nutritional supplement may decrease the barriers for delivery of the at least one Lactobacillus strain.
- the nutritional supplement may be folic acid or a pharmaceutically acceptable salt thereof. It is believed that folic acid or a pharmaceutically acceptable salt thereof may increase the permeability of the gastrointestinal tract. Accordingly, a higher permeability results in a larger uptake of the Lactobacillus strain(s) at the desired site (i.e., the vagina), thereby increasing the “effective dose”.
- the probiotic composition may further comprise lactoferrin. It is believed that lactoferrin increases the stability of the Lactobacillus strain(s), such that the viability of the Lactobacillus strain(s), and therefore amount (CFU count), is higher when stored in the presence of lactoferrin, compared to Lactobacillus strain(s) stored absent lactoferrin.
- carrier layer refers to an impermeable structural element of the multi-component formulation that segregates the probiotic composition and the supplement composition from each other to the extent that the two compositions do not mix.
- identifying refers to detecting or selecting a subject from a population of potential subjects, for example, to establish that a particular subject possesses certain properties or characteristics. “Identifying” may include, for example, self-identification, self-diagnosis, and diagnosis by a medical professional.
- the terms “preventing,” “treating,” “treatment,” “ameliorating,” and the like are used herein to generally refer to obtaining a desired pharmacological and physiological effect and can also refer to a nutritional or nutraceutical effect, the scopes and meanings of which will be clear to the skilled artisan based upon the context in which these terms are used.
- the effect may be prophylactic in terms of preventing or partially preventing a disease, symptom, or condition thereof and''or may be therapeutic in terms of a partial or complete cure of a disease, condition, symptom, or adverse effect attributed to the disease.
- treatment encompasses any treatment of a disease in a mammal, particularly a human and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease or arresting its development; or (c) relieving the disease, causing regression of the disease and/or its symptoms, conditions, and co-morbidities.
- compositions described herein can also be administered to treat, ameliorate, prevent, or reduce vaginal odor, vaginal itching, vaginal discharge, and painful urination that are not caused by BV or yeast infections.
- the term “excipient” refers to any compound that is part of a formulation that is not an active ingredient, i.e., one that has no relevant biological activity, and which is added to the formulation to provide specific characteristics to the dosage form, including by way of example, providing protection to the active ingredient from chemical degradation, facilitating release of a tablet or caplet from equipment in which it is formed, and so forth.
- restoring refers to using the formulations, as described herein, to enact a physiological change within a subject or patient.
- “restoring” or “maintaining,” “healthy” or “optimal” levels of Lactobacilli within the vagina microbiome refers to using the formulations, as described herein, to enact a physiological change within a subject or patient, wherein the physiological change results in the subject or patient developing a vaginal microbiome that comprises at least 90% Lactobacilli.
- “Restoring,” “maintaining,” “healthy” or “optimal” levels of Lactobacilli within the vagina microbiome can also refer to using the formulations, as described herein, to cause a vaginal pH to remain or return to a particular pH, i.e., between about 3.8 and 5.0.
- “restoring” or “maintaining,” “healthy” or “optimal” levels of Lactobacilli within the vagina microbiome refers to using the formulations, as described herein, to enact a physiological change within a subject or patient, wherein the physiological change results in the vaginal microbiome of the subject or patient having a substantially similar vaginal microbiome composition compared to the subject’s or patient’s vaginal microbiome prior to the subject or patient experiencing yeast, BV, symptoms associated therewith, or both.
- the appropriate dosage of the compositions can depend, for example, on the condition to be treated, the severity and course of the condition, whether the composition is administered for preventive or therapeutic purposes, previous therapy, the patient’s clinical history and response to the composition, the type of composition used, and the discretion of the attending physician.
- the composition can be suitably administered to the patient at one time or over a series of treatments and may be administered to the patient at any time from diagnosis onwards.
- the composition may be administered as the sole treatment or in conjunction with other drugs or therapies useful in treating the condition in question.
- the present disclosure comprises supplement compositions and probiotic compositions usefirl for the treatment, prevention, and/or amelioration of BV/yeast and the systems associated therewith.
- Some embodiments provide a multi-component formulation comprising a supplement composition and a probiotic composition, as disclosed herein.
- Embodiments comprising a probiotic composition and supplement composition, described herein present said compositions in an unnatural form, i.e., the probiotic composition and supplement composition comprise components that are present in a form that is different than what occurs naturally.
- “subject” or “patient”, as used herein, refers to a human female.
- the “subject” or “patient” may have BV or yeast, whether or not they show symptoms associated with BV or yeast.
- the “subject” or “patient” may be experiencing symptoms such as vaginal odor, vaginal itching, vaginal discharge, and/or painful urination, whether or not they are diagnosed with an infection.
- the “subject” or “patient” may not have an infection, nor associated symptoms, but may have had BV, yeast, or associated symptoms previously.
- embodiments disclosed herein are effective in treating or ameliorating the symptoms of the “subject” or “patient”, BV, yeast, or both, and are effective in preventing future symptoms of the “subject” or “patient”, BV, yeast or both.
- the present disclosure comprises nutritional and therapeutic oral formulations comprising a probiotic composition and a supplement composition, and methods of using the same.
- Some embodiments provide solid dosage forms of the compositions disclosed herein.
- Some embodiments provide aqueous solutions of compositions disclosed herein.
- Embodiments described herein comprising compositions disclosed herein means that the composition disclosed herein is present in an unnatural form that is different from that which occurs naturally (e.g., in a pill, capsule, and the like formulated as layers present as a powder, solution, and the like), or the oral formulation, probiotic composition, or supplement composition results in unnatural supplementation that is unachievable through a non-supplemented diet.
- An open-label experience trial was be performed to determine the efficacy of treatments for BV or symptoms associated therewith.
- the experience trial participants received a treatment for BV.
- Participants took an oral formulation, which comprised 400 mcg Folate (L-5- Methyltetrahydrofolate), 5 billion CFU of a Lactobacilli blend (e.g., 4 billion CFU Lactobacillis acidophilus and I billion CFU Lactobacillus rhamnosus), and 50 mg of Lactoferrin, which was administered once daily and the results were measured as set forth herein.
- the experience trial started with 31 women and evaluated safety and efficacy endpoints with a vulvovaginal symptoms questionnaire (VSQ) that was sent out at baseline and every two weeks, over the course of 3-6 months.
- VSQ vulvovaginal symptoms questionnaire
- the VSQ collected a rating from trial participants on the severity of vaginal symptoms including vaginal itching, discharge, burning, and odor using a four level scale (absent; mild; moderate; severe).
- the demographics of the subjects was as follows:
- the clinical data demonstrated that the treatment showed that they are efficacious at reducing the symptoms listed on the VSQ.
- the clinical data also demonstrated that the evaluated treatment was safe.
- “safe” refers to the treatment having a statistically insignificant prevalence of symptoms and/or adverse events from the treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Disclosed herein are oral formulations for treating, preventing, or ameliorating symptoms associated with bacterial vaginosis or yeast infections. The oral formulations disclosed herein comprise a probiotic composition and a supplement composition formulated as a single, multi-component formulation. Also described herein are methods utilizing the aforementioned oral formulations.
Description
PROBIOTIC AND FOLIC ACID COMPOSITIONS AND METHODS OF USING
BACKGROUND
The vaginal microbiome plays an essential role in a woman’s health. It is a dynamic environment and experiences variations in the composition of the microbiota during menstrual cycles and as a women ages because of changes in hormonal levels. A healthy vaginal microbiome is dominated by Lactobacillus bacteria; generally, at least 90% of the entire vaginal microbiota comprises Lactobacilli. It is believed that maintaining a healthy Lactobacilli microbiome in the vagina can aid in maintaining a healthy pH (i.e., slightly acidic, pH of about 3.8-45, as a result of the acid-producing Lactobacilli) and causing competitive crowding, thereby preventing infection and other ailments. Accordingly, a loss in abundance of these Lactobacilli can result in higher susceptibility to conditions such as yeast infections and bacterial vaginosis (BV). BV results from replacement of Lactobacilli with anaerobic organisms, such as Gardnerella vaginalis and Atopobium vaginae among others, and results in symptoms such as vaginal discharge, vaginal odor, vaginal itching, and painful urination, all of which may cause discomfort in women. BV is a common condition that affects many women globally, as BV is estimated to impact up to 30% of women in the western world, and up to 50% of women in the developing world.
Treatments for BV according to the prior art generally comprise small-molecules, such as imidazoles, and antibiotics, such as azithromycin, clarithromycin, or erythromycin. Examples of BV treatments are metronidazole, clindamycin, miconazole, tinidazole, and secnidazole. While these treatments, along with other treatments such as yeast treatments, may confer relief of BV and the symptoms associated therewith, there are high rates of recurrence of BV associated with these treatments. Recurrence rates of BV following administration of treatments of the prior art can reach as high as about 30% within 1 month and 50% within 12 months following administration of the treatment. While a definitive explanation for the high recurrence of BV associated with conventional treatments is inconclusive, one theory is that the current therapeutics indiscriminately target bacteria within the vaginal microbiome. Accordingly, the treatments of the prior art kill both the non-beneficial organisms (anaerobes, e.g. , Gardnerella vaginalis and Atopobium vaginae), as well as the beneficial Lactobacilli, thus only temporarily offering relief from BV and inviting a recurrence because of a diminished Lactobacilli content within the vaginal microbiome.
To address these shortcomings, researchers have suggested the use of adjuvant Lactobacilli probiotics to offset the reduction in Lactobacilli following a primary administration of a treatment of the prior art, which have demonstrated some success in preventing BV or yeast recurrence. In other instances, researchers have suggested the use of probiotics alone, or in combination with other non-conventional treatments, i.e., those not conventionally used to treat BV or yeast, to prevent recurrence of such infections. Generally, these treatments are administered intravaginally, which may cause discomfort in a patient seeking treatment, and/or they require long durations of administration (> 1 month), which may result in lower patient compliance.
In light of these discoveries, the inventors have identified a growing demand to develop formulations to treat, prevent, or ameliorate BV, yeast, or the symptoms associated therewith, while ensuring maximal patient comfort and compliance. The inventors have noted the relationship between the vaginal microbiome and its role in BV, yeast, or symptoms associated therewith. Accordingly, the inventors have found that administering an oral multi-component formulation, comprising a probiotic composition of at least one Lactobacillus strain concurrently with at least one nutritional supplement provides superior, and unexpected benefits, compared to the individual components alone. Such a finding is novel and remains to be seen in the prior art. As such, by providing a probiotic composition and a nutritional supplement together as pharmaceutical agents and/or dietary supplements, therapeutic and nutraceutical benefits can be realized, either individually, collectively, or in conjunction with other pharmaceutical agents and/or dietary supplements.
SUMMARY
Embodiments of the present disclosure relate to novel oral formulations comprising at least one probiotic Lactobacillus bacteria and at least one nutritional supplement and their use in the amelioration, prevention, and/or treatment of the symptoms associated with BV or yeast infections.
These and other feature, aspects, and advantages of the present embodiments will become understood with reference to the following description, appended claims, and accompanying figures.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a table demonstrating results from respondents that provided responses to survey questions concerning their emotions regarding the foregoing symptoms and respondents
reported improvements to their levels of frustration, worry about symptoms, embarrassment, levels of affection, and levels of intimate desire.
DETAILED DESCRIPTION
Some embodiments provide a composition comprising an amount of at least one Lactobacillus species formulated as a probiotic composition. The Lactobacillus species can be Lactobacillus jensenii, Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus casei, Lactobacillus salivarius, Lactobacillus gasseri, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus brevis, Lactobacillus reuteri, Lactobacillus bulgaricus, Lactobacillus crispatus, Lactobacillus johnsonii, Lactobacillus helveticus, or any combination thereof. Some embodiments can be formulated to have varying amounts of these one or more Lactobacillus species.
In some embodiments, a probiotic composition can comprise a first Lactobacillus species and a second Lactobacillus species, wherein the first Lactobacillus species and the second Lactobacillus species are formulated in a ratio. In certain embodiments, a ratio of the first Lactobacillus species and the second Lactobacillus species can be about 4: 1 In certain embodiments, a ratio of the first Lactobacillus species and the second Lactobacillus species can be about 1: 1. In some embodiments, a ratio of the first Lactobacillus species and the second Lactobacillus species can be within the range of about 10:1 to about 1 : 10. In this regard, a ratio of the first Lactobacillus species and the second Lactobacillus species may be about 2: 1 , about 3: 1, about 4: 1, about 5: 1, about 6:1 , about 7: 1, about 8:1, about 9: 1, about 10: 1, about 1:2, about 1 :3, about 1 :4, about 1 :5, about 1 :6, about 1 :7, about 1 :8, about 1 :9, or about 1 :10.
In some embodiments, a probiotic composition can comprise an amount of at least one Lactobacillus species of about 1 billion CFU to about 20 billion CFU, or any ratio in between. For example, in some embodiments the amount of the at least one Lactobacillus species can be about 1 billion CFU to about 4 billion CFU. Some embodiments can comprise an amount of at least one Lactobacillus species of about 4 billion or more CFU. In certain embodiments, the amount of the at least one Lactobacillus species can be about 4 billion CFU to about 10 billion CFU. In some embodiments, the amount of the at least one Lactobacillus species can be about 10 billion CFU to about 20 billion CFU.
In some embodiments, a probiotic composition can comprise an amount of a first Lactobacillus species and a second Lactobacillus species. In certain embodiments, the amount of both the first Lactobacillus species and second Lactobacillus species can be about 1 billion CFU to about 5 billion CFU. Some embodiments can comprise an amount of a first Lactobacillus species and a second Lactobacillus species of about 5 billion or more CFU. In certain
embodiments, the amount of both the first Lactobacillus species and second Lactobacillus species can be about 5 billion CPU to about 10 billion CFU. In some embodiments, the amount of both the first Lactobacillus species and second Lactobacillus species can be about 10 billion CFU to about 20 billion CFU. In certain embodiments, the amount of the first Lactobacillus species can be about 1 billion CFU to about 5 billion CFU and second Lactobacillus species can be about 5 billion CFU to about 10 billion CFU. In some embodiments, the amount of the first Lactobacillus species can be about 1 billion CFU to about 5 billion CFU and second Lactobacillus species can be about 10 billion CFU to about 20 billion CFU. In some embodiments, the amount of the first Lactobacillus species can be about 5 billion CFU to about 10 billion CFU and second Lactobacillus species can be about 1 billion CFU to about 5 billion CFU. In certain embodiments, the amount of the first Lactobacillus species can be about 5 billion CFU to about 10 billion CFU and second Lactobacillus species can be about 10 billion CFU to about 20 billion CFU. In some embodiments, the amount of the first Lactobacillus species can be about 10 billion CFU to about 20 billion CFU and second Lactobacillus species can be about 1 billion CFU to about 5 billion CFU. In certain embodiments, the amount of the first Lactobacillus species can be about 10 billion CFU to about 20 billion CFU and second Lactobacillus species can be about 5 billion CFU to about 10 billion CFU.
In some embodiments, an oral formulation, as described herein, may comprise at least one probiotic Lactobacillus bacteria and at least one nutritional supplement, as described herein. Certain embodiments comprise a method of balancing the vaginal microbiome, the method comprising: identifying a subject with a pH level above about 4.5; administering an oral multicomponent formulation, wherein the oral multi-component formulation comprises: a probiotic composition layer, wherein the probiotic composition layer comprises an amount of at least one Lactobacillus species; a supplement composition layer, wherein the supplement composition layer comprises an amount of at least one nutritional supplement ingredient; and a middle barrier layer disposed between the probiotic composition layer and the supplement composition layer, wherein the probiotic composition layer and the supplement composition layer are positioned on opposing sides of the middle barrier layer.
Certain embodiments comprise a method of regulating, restoring, or balancing the vaginal pH of a subject, the method comprising: identifying a subject in need thereof; administering an oral formulation of one or more formulations as set forth herein. In some embodiments, the oral formulation is a multi-component formulation. In some embodiments, the oral formulation comprises one or more of a probiotic composition and a nutritional supplement.
In some embodiments, a probiotic composition may further comprise an amount of at least one additional additive that reduces sensitivity to moisture and/or prolongs shelf-life of the probiotic composition. In some embodiments, the amount of the at least one additional additive can be between about 10 mg and about 500 mg. For example, the amount of the at least one additional additive in the probiotic composition may be about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, or any range or amount in between any two of the preceding values and any other ranges or amounts disclosed herein. In certain embodiments, the at least one additional additive may be lactoferrin. In certain embodiments, the additional additive may be lactoferrin, and the probiotic composition may comprise an amount of lactoferrin between about 10 mg and about 500 mg. For example, the amount of lactoferrin in the probiotic composition can be about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, or any range or amount in between any two of the preceding values and any other ranges or amounts disclosed herein.
Some embodiments provide a composition comprising at least one nutritional supplement ingredient formulated as a supplement composition.
In certain embodiments, the at least one nutritional supplement ingredient can be an essential fatty acid, such as linolenic acid or linoleic acid, or an essential amino acid, such as tryptophan, lysine, methionine, phenylalanine, threonine, valine, leucine, isoleucine, arginine, or histidine, or any combination thereof.
In some embodiments, the at least one nutritional supplement ingredient can be a vitamin, such as retinol (vitamin A), thiamine (vitamin Bl), riboflavin (vitamin B2), niacin (vitamin B3), pantothenic acid (vitamin B5), pyridoxine, pyridoxamine, or pyridoxal (vitamin B6), biotin (vitamin B7) or pharmaceutically acceptable salts thereof, folic acid (vitamin B9) or pharmaceutically acceptable salts thereof, cobalamin (vitamin B12), choline, ascorbic acid (vitamin C) or pharmaceutically acceptable salts thereof, ergocalciferol (vitamin D2), calciferol (vitamin D3), 22-dihydroergocalciferol (vitamin D4), sitocalciferol (vitamin D5), tocopherol (vitamin E), phylloquinone (vitamin KI), menaquinone (vitamin K2), menadione (vitamin K3), or any combination of the foregoing.
In some embodiments, the at least one nutritional supplement ingredient can be a dietary’ mineral, such as chromium, including, chromium polynicotinate, chromium acetate, chromium
histidinate, chromium nicotinate, chromium chloride, and the like, or any or any pharmaceutically acceptable salts, hydrates, solvates, or mixtures thereof, bromine, cobalt, copper, fluorine, germanium, iodine, iron, magnesium, manganese, molybdenum, potassium, selenium, silicon, zinc, calcium, phosphorous, sodium, sulfur, vanadium, or any combination thereof.
In certain embodiments, the at least one nutritional supplement ingredient can be n-acetyl cysteine, nicotinamide riboside, resveratrol, NAD+ precursors, Coenzyme Q10, reduced Coenzyme Q10, omega-3-fatty acids, bee pollen, cabbage powder, pterostilbene, nicotinamide mononucleotide, cranberry extract, turmeric or an extract thereof, royal jelly, acai berry, beet root or an extract thereof, coral calcium, oyster shell, Gotu kola or an extract thereof. Gingko biloba or an extract thereof, lions mane mushroom, pomegranate, hibiscus flower, strawberry powder, dandelion root, celery powder, parsley powder, peppermint leaf, cinnamon bark powder, maca root, phycocyanin or an extract thereof, pumpkin seed or an extract thereof, Crataeva nurvala or an extract thereof, Lindera aggregata or an extract thereof, citrulline nitrate, creatine nitrate, beta-alanine, beta-alanine nitrate, or any combination thereof.
In some embodiments, the amount of the nutritional supplemental ingredient, disclosed herein, can be about 10 μg to about 1 g. For example, the amount of the composition can be about 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 55 μg, 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, 100 μg, 125 μg, 150 μg, 175 μg, 200 μg, 225 μg, 250 μg, 275 μg, 300 μg, 325 μg, 350 μg, 375 μg, 400 μg, 425 μg, 450 μg, 475 μg, 500 μg, 525 μg, 575 μg, 600 μg, 625 μg, 650 μg, 675 μg, 700 μg, 725 μg, 750 μg, 775 μg, 800 μg, 825 μg, 850 μg, 875 μg, 900 μg, 925 μg, 950 μg, 975 μg, 1000 μg, 5 mg, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 825 mg, 850 mg, 875 mg, 900 mg, 925 mg, 950 mg, 975 mg, 1000 mg, or any range or amount in between any two of the preceding values and any other ranges or amounts disclosed herein.
Some embodiments can be formulated as a multi-component formulation that can comprise a nutritional supplement and/or a probiotic composition, as disclosed herein, disposed as the center layer of the formulation, a nutritional supplement composition, as disclosed herein, disposed as the outer layer of the formulation, and a middle barrier layer disposed therebetween, wherein the probiotic composition layer and the nutritional supplement composition layer are positioned on opposing sides of the middle barrier layer. A multi-component formulation can be formulated as a tablet, a hard capsule, a soft capsule, a plant-derived capsule, gel capsule, caplet.
or the iike. The probiotic composition can be formulated as a solid, such as a powder, granule, amorphous solid, crystalline solid, or the like, and the nutritional supplement can be formulated as a solid, such as a powder, granule, amorphous solid, crystalline solid or the composition can be formulated as a liquid, such as an aqueous solution, an oil-based solution, an aqueous suspension, an oil suspension, an emulsion, a syrup, an elixir, or the like. Some embodiments can comprise a combination of the foregoing forms of formulations.
In certain embodiments, a multi-component formulation can be formulated as a tablet, a hard capsule, a soft capsule, a plant-derived capsule, gel capsule, caplet, or the like. The multicomponent formulation can comprise a probiotic composition disposed as a layer, a nutritional supplement composition disposed as a layer, and a barrier layer disposed therebetween, wherein the probiotic composition layer and the supplement composition layer are positioned on opposing sides of the middle barrier layer. The probiotic composition can be formulated as a solid, such as a powder, a granule, particles, an amorphous solid, a crystalline solid, or the like, and the nutritional supplement can be formulated as a solid, such as a powder, granule, amorphous solid, crystalline solid or the composition can be formulated as a liquid, such as an aqueous solution, an oil-based solution, an aqueous suspension, an oil suspension, an emulsion, a syrup, an elixir, or the like. Some embodiments can comprise a combination of the foregoing forms of formulations.
In certain embodiments, the middle barrier layer, as described herein, can be comprised of excipients that would separate the probiotic composition from the supplement composition. The barrier layer can be included in the formulation by art-recognized coating or layering procedures. The barrier layer may be comprised of pharmaceutically acceptable compounds such as, for example, sugar-, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose sodium and others, used alone or in mixtures. Additives such as plasticizers, colorants, pigments, fillers, anti-tacking and anti-static agents including magnesium stearate, titanium dioxide, talc, and other additives can optionally be included in the barrier layer. In some embodiments, the middle barrier portion is comprised of a controlled release, delayed release, or enteric coating to control or delay the release of the inner contents of the formulation.
In some embodiments, the multi-component formulation, as described herein, includes an outer coating. The outer coating serves to provide an immediate release, controlled-release, delayed-release, or enteric-coating to control or delay the release of the supplement composition and probiotic composition. The outer coating layer (or layers) can be applied by coating or
layering procedures which are well-established in the relevant arts. The outer coating layer can be at least one of a pharmaceutically acceptable compound selected from the group consisting of sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose sodium and combinations thereof. Additives including plasticizers, colorants, pigments, fillers, anti-tacking, and anti-static agents can optionally be included in the outer coating. In some embodiments, the outer coating regulates release of the supplement composition and/or probiotic composition from the tablet, capsule, caplet, or the like. Controlled-release, delayed-release, and/or enteric-coating technology is well-established in the pharmaceutical and formulation arts. Compositions described herein can be formulated as sustained or slow release, designed to be released into the gastrointestinal tract of a patient at a specified rate of delivery.
In some embodiments, a probiotic composition, a supplement composition, a middle barrier layer, and/or an outer coating, as described herein, may include one or more excipients, such as the following classes of agents: sweeteners, flavoring agents, coloring agents, coatings, preservatives, lubricants, binders, surfactants, fillers, disintegrants, suspending agents, dispersing agents, wetting agents, thickening agents. In certain embodiments, the one or more excipients may be one or more of glycerin, hydroxypropyl methylcellulose, microcrystalline cellulose, magnesium stearate, silicon dioxide, calcium carbonate, sodium carbonate, lactose, calcium phosphate, sodium phosphate, corn starch, alginic acid, starch, gelatin, acacia, stearic acid, talc, glyceryl monostearate, glyceryl distearate, kaolin, peanut oil, liquid paraffin, olive oil, arachis oil, sesame oil, coconut oil, sucrose, saccharin, beeswax, hard paraffin, xanthan gum, cetyl alcohol, sorbitol, or any combination of the foregoing. The excipients that may be included in any composition, a middle layer, or a coating, as described herein, are not particularly limited.
In certain embodiments, a multi-component formulation comprising a probiotic composition and a supplement composition, according to the disclosure, can be administered to a subject to treat, ameliorate, or prevent BV or yeast infections. In some embodiments, a multicomponent formulation comprising a probiotic composition and a supplement composition, as described herein, can be administered to a subject to treat, ameliorate, or prevent in a subject experiencing symptoms associated with BV or yeast infections, such as vaginal odor, vaginal itching, vaginal discharge, painful urination, or any combination thereof, even if the subject does not have BV or a yeast infection.
In some embodiments, a multi-component formulation comprising a probiotic composition and a supplement composition, according to the disclosure, can be administered to
a subject to restore or maintain healthy or optimal levels of Lactobacilli within the vaginal microbiome.
In some embodiments, a multi-component formulation comprising a probiotic composition and a supplement composition to prevent BV/yeast, vaginal odor, vaginal itching, vaginal discharge, painful urination, or any combination thereof, as described herein, can be administered to a subject at least once daily for a periodic cycle. In certain embodiments, a periodic cycle of at least once daily administration can comprise administering the formulation to a subject once a day for about 2 consecutive days to about 20 consecutive days. For example, a periodic cycle of at least once daily administration can comprise administering the formulation to a subject once a day for about 15 consecutive days. In some embodiments, the periodic cycle of at least once daily administration may be repeated on a monthly basis. For example, a periodic cycle of at least once daily administration may comprise administering the formulation to a subject once a day for about 15 consecutive days, and the periodic cycle may be repeated monthly for at least one month consecutively, six months consecutively, twelve months consecutively, or longer. A dosage cycle can be one dose per month, one dose every 15 days, one dose every 10 days, one dose every 5 days, one dose ever two days, or daily dosage.
In certain embodiments, treating, ameliorating, or preventing yeast/BV, vaginal odor, vaginal itching, vaginal discharge, painful urination, or any combination thereof, may result in symptomatic improvement in a subject after about one periodic cycle, as described herein. For example, after being administered a formulation, as disclosed herein, for 15 consecutive days for 1 month consecutively, a subject may observe amelioration and/or treatment of BV or symptoms associated therewith. Additionally, after being administered a formulation, as disclosed herein, for 15 consecutive days for 1 month consecutively, a subject may be more likely to be prevented from contracting BV or experiencing a symptom associated therewith.
Without being bound by any particular theory, it is believed that yeast infections, BV or the symptoms associated therewith result from a reduction in the concentration of Lactobacilli within the vaginal microbiota. Accordingly, it is believed that by supplementing the vaginal microbiota with Lactobacilli, BV, yeast or its associated symptoms can be treated, prevented, ameliorated. It is believed that the embodiments disclosed herein maintain and/or restore concentration of Lactobacilli within the vaginal microbiome to healthy or optimum levels through multiple mechanisms.
First, it is believed that providing at least one Lactobacillus strain effectively restores the Lactobacilli content of the vaginal microbiome by directly increasing the Lactobacilli content, and in some instances, by controlling growth of other microorganisms (non-Lactobacilli) within
the vaginal flora. For example, in some embodiments, the at least one Lactobacillus strain may be Lactobacillus acidophilus, which ferments sugar to produce lactic acid and thrives in an acidic environment (pH < 5). Both the lactic acid compound and a low pH (a consequence of circulating lactic acid) may be hostile to non-Lactobacilli microorganisms, thereby increasing the relative concentration of Lactobacilli in the vaginal microbiome.
Second, by co-administering at least one Lactobacillus strain with a nutritional supplement, it is believed that that the nutritional supplement increases the effective amount of Lactobacilli delivered to the vagina. It is also believed that the nutritional supplement increases the viability of the at least one Lactobacillus strain once in the body of a subject. For example, in some embodiments, the nutritional supplement may be folic acid or a pharmaceutically acceptable salt thereof. It is believed that folic acid or a pharmaceutically acceptable salt thereof increases the amount (CFU count) of the Lactobacillus strain(s) once the formulation is within the body and the nutritional supplement and Lactobacillus strain(s) “mix” (they are separated in different compartments within the multi-component formulation), such that the amount (CFU count) of the Lactobacillus strain(s) is significantly higher in the presence of folic acid or a pharmaceutically acceptable salt thereof compared to the an amount (CFU count) of the Lactobacillus strain(s) that would exist were no folic acid or a pharmaceutically acceptable salt thereof present. This increase results in a higher “effective dose” in the formulation, and therefore a higher dose being delivered to the vagina of the individual receiving treatment. It is also believed that the nutritional supplement may decrease the barriers for delivery of the at least one Lactobacillus strain. For example, in some embodiments, the nutritional supplement may be folic acid or a pharmaceutically acceptable salt thereof. It is believed that folic acid or a pharmaceutically acceptable salt thereof may increase the permeability of the gastrointestinal tract. Accordingly, a higher permeability results in a larger uptake of the Lactobacillus strain(s) at the desired site (i.e., the vagina), thereby increasing the “effective dose”.
Third, by incorporating additional additives that reduce sensitivity to moisture with the at least one Lactobacillus strain, it is believed that the effective amount of Lactobacilli in a formulation remains at a higher level than what would were no additional additive present. For example, in some embodiments, the probiotic composition may further comprise lactoferrin. It is believed that lactoferrin increases the stability of the Lactobacillus strain(s), such that the viability of the Lactobacillus strain(s), and therefore amount (CFU count), is higher when stored in the presence of lactoferrin, compared to Lactobacillus strain(s) stored absent lactoferrin. Accordingly, this increase results in a higher “effective dose” in the formulation, and therefore a higher dose being delivered to the vagina of the individual receiving treatment
As used herein, the term “barrier layer” refers to an impermeable structural element of the multi-component formulation that segregates the probiotic composition and the supplement composition from each other to the extent that the two compositions do not mix.
As used herein, the term “identifying” refers to detecting or selecting a subject from a population of potential subjects, for example, to establish that a particular subject possesses certain properties or characteristics. “Identifying” may include, for example, self-identification, self-diagnosis, and diagnosis by a medical professional.
As used herein, the terms “preventing,” “treating,” “treatment,” “ameliorating,” and the like are used herein to generally refer to obtaining a desired pharmacological and physiological effect and can also refer to a nutritional or nutraceutical effect, the scopes and meanings of which will be clear to the skilled artisan based upon the context in which these terms are used. The effect may be prophylactic in terms of preventing or partially preventing a disease, symptom, or condition thereof and''or may be therapeutic in terms of a partial or complete cure of a disease, condition, symptom, or adverse effect attributed to the disease. The term “treatment” as used herein encompasses any treatment of a disease in a mammal, particularly a human and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease or arresting its development; or (c) relieving the disease, causing regression of the disease and/or its symptoms, conditions, and co-morbidities.
As used herein, the meaning of the terms “vaginal odor,” “vaginal itching,” “vaginal discharge,” and “painful urination” would immediately be envisaged by the skilled artisan. The etiology’ of these terms would be understood by the skilled artisan to refer to the common symptoms resulting from BV or yeast. However, compositions described herein can also be administered to treat, ameliorate, prevent, or reduce vaginal odor, vaginal itching, vaginal discharge, and painful urination that are not caused by BV or yeast infections.
As used herein, the term “excipient” refers to any compound that is part of a formulation that is not an active ingredient, i.e., one that has no relevant biological activity, and which is added to the formulation to provide specific characteristics to the dosage form, including by way of example, providing protection to the active ingredient from chemical degradation, facilitating release of a tablet or caplet from equipment in which it is formed, and so forth.
As used herein, the term “restoring” or “maintaining” refers to using the formulations, as described herein, to enact a physiological change within a subject or patient. In some embodiments, “restoring” or “maintaining,” “healthy” or “optimal” levels of Lactobacilli within the vagina microbiome refers to using the formulations, as described herein, to enact a
physiological change within a subject or patient, wherein the physiological change results in the subject or patient developing a vaginal microbiome that comprises at least 90% Lactobacilli. “Restoring,” “maintaining,” “healthy” or “optimal” levels of Lactobacilli within the vagina microbiome can also refer to using the formulations, as described herein, to cause a vaginal pH to remain or return to a particular pH, i.e., between about 3.8 and 5.0. In some embodiments, “restoring” or “maintaining,” “healthy” or “optimal” levels of Lactobacilli within the vagina microbiome refers to using the formulations, as described herein, to enact a physiological change within a subject or patient, wherein the physiological change results in the vaginal microbiome of the subject or patient having a substantially similar vaginal microbiome composition compared to the subject’s or patient’s vaginal microbiome prior to the subject or patient experiencing yeast, BV, symptoms associated therewith, or both.
To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term “about.” It is understood that whether the term “about” is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including approximations due to the experimental and/or measurement conditions for such given value.
In addition, the appropriate dosage of the compositions can depend, for example, on the condition to be treated, the severity and course of the condition, whether the composition is administered for preventive or therapeutic purposes, previous therapy, the patient’s clinical history and response to the composition, the type of composition used, and the discretion of the attending physician. The composition can be suitably administered to the patient at one time or over a series of treatments and may be administered to the patient at any time from diagnosis onwards. The composition may be administered as the sole treatment or in conjunction with other drugs or therapies useful in treating the condition in question.
The present disclosure comprises supplement compositions and probiotic compositions usefirl for the treatment, prevention, and/or amelioration of BV/yeast and the systems associated therewith. Some embodiments provide a multi-component formulation comprising a supplement composition and a probiotic composition, as disclosed herein. Embodiments comprising a probiotic composition and supplement composition, described herein, present said compositions in an unnatural form, i.e., the probiotic composition and supplement composition comprise components that are present in a form that is different than what occurs naturally.
For the purpose of this disclose, “subject” or “patient”, as used herein, refers to a human female. In certain embodiments, the “subject” or “patient” may have BV or yeast, whether or
not they show symptoms associated with BV or yeast. In other embodiments, the “subject” or “patient” may be experiencing symptoms such as vaginal odor, vaginal itching, vaginal discharge, and/or painful urination, whether or not they are diagnosed with an infection. In some embodiments, the “subject” or “patient” may not have an infection, nor associated symptoms, but may have had BV, yeast, or associated symptoms previously. In all instances, embodiments disclosed herein are effective in treating or ameliorating the symptoms of the “subject” or “patient”, BV, yeast, or both, and are effective in preventing future symptoms of the “subject” or “patient”, BV, yeast or both.
The present disclosure comprises nutritional and therapeutic oral formulations comprising a probiotic composition and a supplement composition, and methods of using the same. Some embodiments provide solid dosage forms of the compositions disclosed herein. Some embodiments provide aqueous solutions of compositions disclosed herein. Embodiments described herein comprising compositions disclosed herein means that the composition disclosed herein is present in an unnatural form that is different from that which occurs naturally (e.g., in a pill, capsule, and the like formulated as layers present as a powder, solution, and the like), or the oral formulation, probiotic composition, or supplement composition results in unnatural supplementation that is unachievable through a non-supplemented diet.
EXAMPLES
Example 1
An open-label experience trial was be performed to determine the efficacy of treatments for BV or symptoms associated therewith. The experience trial participants received a treatment for BV. Participants took an oral formulation, which comprised 400 mcg Folate (L-5- Methyltetrahydrofolate), 5 billion CFU of a Lactobacilli blend (e.g., 4 billion CFU Lactobacillis acidophilus and I billion CFU Lactobacillus rhamnosus), and 50 mg of Lactoferrin, which was administered once daily and the results were measured as set forth herein.
The experience trial started with 31 women and evaluated safety and efficacy endpoints with a vulvovaginal symptoms questionnaire (VSQ) that was sent out at baseline and every two weeks, over the course of 3-6 months. The VSQ collected a rating from trial participants on the severity of vaginal symptoms including vaginal itching, discharge, burning, and odor using a four level scale (absent; mild; moderate; severe). The demographics of the subjects was as follows:
Age: 47.3 +/- 15.1 yrs
Height: 63.4 +/- 2.2 inches
Body Weight: 159.3 +/- 28.8 lbs
BMI (kg/m2): 28.0 +/- 5.4
22 Wliile/Caiicasian. 3 Biack/African American, 6 Hispanic
Regarding efficacy, the clinical data demonstrated that the treatment showed that they are are efficacious at reducing the symptoms listed on the VSQ. The clinical data also demonstrated that the evaluated treatment was safe. Herein, “safe” refers to the treatment having a statistically insignificant prevalence of symptoms and/or adverse events from the treatment.
The results obtained in the treatment were as follows:
When asked if “during the past week have you experienced odor from your vulva or vagina,” respondents (n=31) reported significant reductions at weeks 2, 4, 6, 8, 10, and 12 (p<0.001) from baseline (Week 0), as follows:
When asked to rate the severity of their vaginal odor over the past week (absent, mild, moderate, severe), respondents (n=31) starting with a baseline reporting of mild to severe symptoms reported significant reductions at weeks 2, 4, 6, 8, 10, and 12 (p<0.001) as follows:
Mild, moderate, and severe subjects reporting a reduction.
When asked to rate the severity of their vaginal odor over the past week (absent, mild, moderate, severe), respondents (n=21) starting with a baseline reporting of moderate to severe symptoms reported significant reductions at weeks 2, 4, 6, 8, 10, and 12 (p<0.001) as follows:
Moderate and severe subjects reporting a reduction
When asked to rate the severity of their vaginal itching over the past week (absent, mild, moderate, severe), respondents (n=15) starting with a baseline reporting of mild to severe symptoms reported significant reductions at weeks 6, 8, 10, and 12 (p<0.01) as follows:
Mild, moderate, and severe subjects reporting a reduction
When asked to rate the severity of their vaginal irritation over the past week (absent, mild, moderate, severe), respondents (n=19) starting with a baseline reporting of mild to severe symptoms reported significant reductions at weeks 10 and 12 (p<0.01) as follows:
Mild, moderate, and severe subjects reporting a reduction
When asked to rate the severity of their vaginal dryness over the past week (absent, mild, moderate, severe), respondents (n=25) starting with a baseline reporting of mild to severe symptoms reported significant reductions at weeks 4 and 12, along with a sustained reduction in the severity of the dryness over weeks two through 12, as follows:
Mild, moderate, and severe subjects reporting a reduction
When asked to rate the severity of their vaginal burning over the past week (absent, mild, moderate, severe), respondents (n=14) starting with a baseline reporting of mild to severe symptoms reported significant reductions at weeks 4, 8, 10 and 12 (p<0.05) as follows:
Mild, moderate, and severe subjects reporting a reduction
Respondents also provided responses to survey questions concerning their emotions regarding the foregoing symptoms and respondents reported improvements to their levels of frustration, worry about symptoms, embarrassment, levels of affection, and levels of intimate desire. These results are shown in Fig 1.
Additional testing will be conducted following similar protocols wherein compounds of the disclosure will be administered to subjects to ascertain improvements in the severity of vaginal symptoms including itching, discharge, burning, odor, pain during sexual intercourse,
spotting (bleeding) during sexual intercourse, along with other metrics such as sexual desire and pleasure during intercourse.
While the present invention has been described in some detail for purposes of clarity and understanding, one will appreciate that the present invention has been described in some detail for purposes of clarity and understanding, one will appreciate that various changes in form and detail can be made without departing from the true scope of the invention.
Claims
1. An oral multi-component formulation, the multi-component formulation comprising: a probiotic composition layer, wherein the probiotic composition layer comprises an amount of at least one Lactobacillus species; a supplement composition layer, wherein the supplement composition layer comprises an amount of at least one nutritional supplement ingredient; and a middle barrier layer disposed between the probiotic composition layer and the supplement composition layer, wherein the probiotic composition layer and the supplement composition layer are positioned on opposing sides of the middle barrier layer.
2. The oral multi-component formulation of claim 1, wherein the probiotic composition layer comprises an amount of Lactobacillus acidophilus and an amount Lactobacillus rhamnosus.
3. The oral multi-component formulation of claim 2, wherein the Lactobacillus acidophilus is Lactobacillus acidophilus and the Lactobacillus rhamnosus is Lactobacillus rhamnosus.
4. The oral multi-component formulation of claim 2, wherein a ratio of the amount of Lactobacillus acidophilus to the amount of Lactobacillus rhamnosus is about 4:1.
5. The oral multi-component formulation of claim 1, wherein the at least one nutritional supplement ingredient comprises an amount folic acid or a pharmaceutically acceptable salt of folate.
6. The oral multi-component formulation of claim 2, wherein the at least one nutritional supplement ingredient comprises an amount of folic acid or a pharmaceutically acceptable salt of folate.
7. The oral multi-component formulation of claim 4, wherein the at least one nutritional supplement ingredient comprises an amount folic acid or a pharmaceutically acceptable salt of folate.
8. The oral multi-component formulation of claim 1, wherein the probiotic composition layer further comprises an amount of lactoferrin.
9. The oral multi-component formulation of claim 6, wherein the probiotic composition layer further comprises an amount of lactoferrin.
10. The oral multi-component formulation of claim 7, wherein the probiotic composition layer further comprises an amount of lactoferrin.
11. A method of balancing the vaginal microbiome, the method comprising:
identifying a subject with a pH ievel above about 4.5; administering an orai multi-component formulation, wherein the oral multicomponent formulation comprises: a probiotic composition layer, wherein the probiotic composition layer comprises an amount of at least one Lactobacillus species; a supplement composition layer, wherein the supplement composition layer comprises an amount of at least one nutritional supplement ingredient; and a middle barrier layer disposed between the probiotic composition layer and the supplement composition layer, wherein the probiotic composition layer and the supplement composition layer are positioned on opposing sides of the middle barrier layer.
12. The method of claim 11, wherein the oral multi-component formulation is administered once per month.
13. The method of claim 12, wherein the oral multi-component formulation is administered once every’ 15 days.
14. The method of claim 11, wherein the probiotic composition layer comprises an amount of Lactobacillus acidophilus and an amount Lactobacillus rhamnosus, and the at least one nutritional supplement ingredient comprises an amount of folic acid or a pharmaceutically acceptable salt of folate.
15. The method of claim 11 , wherein the probiotic composition layer further comprises an amount of lactoferrin.
16. A method of treating, preventing, or ameliorating at least one symptom selected from the group consisting of vaginal odor, vaginal discharge, vaginal itching, painful urination, and any combination thereof, the method comprising: identifying the at least one symptom in the subject; administering an oral multi-component formulation, wherein the oral multicomponent formulation comprises: a probiotic composition layer, wherein the probiotic composition layer comprises an amount of at least one Lactobacillus species; a supplement composition layer, wherein the supplement composition layer comprises an amount of at least one nutritional supplement ingredient; and a middle barrier layer disposed between the probiotic composition layer and the supplement composition layer, wherein the probiotic composition layer
and the supplement composition layer are positioned on opposing sides of the middle barrier layer.
17. The method of claim 16. wherein the subject has bacterial vaginosis.
18. The method of claim 16, wherein the subject does not have bacterial vaginosis.
19. The method of claim 16, wherein the probiotic composition layer comprises an amount of Lactobacillus acidophilus and an amount Lactobacillus rhamnosus, and the at least one nutritional supplement ingredient comprises an amount of folic acid or a pharmaceutically acceptable salt of folate.
20. The method of claim 16, wherein the probiotic composition layer further comprises an amount of lactoferrin.
21. A method of regulating, restoring, or balancing the vaginal pH of a subject, the method comprising: identifying a subject in need thereof; administering an oral formulation to regulate, restore, or balance the vaginal pH of the subject.
22. The method of claim 21, wherein the vaginal pH of the subject is regulated, restored, or balanced between about 3.8 and 5.0.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2022/045473 WO2024072421A1 (en) | 2022-09-30 | 2022-09-30 | Probiotic and folic acid compositions and methods of using |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2022/045473 WO2024072421A1 (en) | 2022-09-30 | 2022-09-30 | Probiotic and folic acid compositions and methods of using |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024072421A1 true WO2024072421A1 (en) | 2024-04-04 |
Family
ID=90478888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/045473 WO2024072421A1 (en) | 2022-09-30 | 2022-09-30 | Probiotic and folic acid compositions and methods of using |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024072421A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010081126A2 (en) * | 2009-01-12 | 2010-07-15 | Wyeth Llc | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin |
WO2021247571A1 (en) * | 2020-06-01 | 2021-12-09 | Ferring B.V. | Vaginal microbiota compositions |
US11241388B2 (en) * | 2007-06-26 | 2022-02-08 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
WO2022185121A1 (en) * | 2021-03-03 | 2022-09-09 | Freya Biosciences Aps | Vaginal microbiota-associated methods, compositions, and devices |
-
2022
- 2022-09-30 WO PCT/US2022/045473 patent/WO2024072421A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11241388B2 (en) * | 2007-06-26 | 2022-02-08 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
WO2010081126A2 (en) * | 2009-01-12 | 2010-07-15 | Wyeth Llc | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin |
WO2021247571A1 (en) * | 2020-06-01 | 2021-12-09 | Ferring B.V. | Vaginal microbiota compositions |
WO2022185121A1 (en) * | 2021-03-03 | 2022-09-09 | Freya Biosciences Aps | Vaginal microbiota-associated methods, compositions, and devices |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE502007010071C5 (en) | USE OF A MINERAL COMPOSITION AND, WHERE APPROPRIATE, ACETOGENIC AND / OR BUTYROGENIC BACTERIA TO AVOID OR REDUCE GAS FORMATION IN THE THICKNESS OF ANIMALS AND THEREFORE COMPLAINED ABDOMINAL | |
US8192733B2 (en) | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions | |
US7749509B2 (en) | Treatment of autism using probiotic composition | |
EP2315582B1 (en) | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions | |
US20070280912A1 (en) | Treatment of irritable bowel syndrome using probiotic composition | |
US20080051459A1 (en) | Long term 24-hour intestinal administration of levodopa/carbidopa | |
US20200306325A1 (en) | Probiotic consortia for oral health | |
WO2007038466A2 (en) | Treatment of bipolar disorder utilizing anti-fungal compositions | |
JP2021508321A (en) | Compositions for use in the treatment and / or amelioration of sleep and mood disorders | |
US20130022577A1 (en) | Probiotic compositions useful for treatment of bipolar disorder | |
CN116367823A (en) | Direct delivery of vitamins to inhibit microbial pathogens | |
WO2018187467A1 (en) | Compositions and methods for treating parkinson's disease (pd) and related disorders | |
AU2018310609B2 (en) | Composition for use in the prevention and/or treatment of oncologic treatment induced Orogastrointestinal Mucositis | |
US20240108048A1 (en) | Probiotic and folic acid compositions and methods of using | |
WO2024072421A1 (en) | Probiotic and folic acid compositions and methods of using | |
US20230293578A1 (en) | Treatment of bacterial vaginosis | |
US20070065504A1 (en) | Products and methods for treating vaginal infections | |
KR20230097085A (en) | Direct delivery of vitamins to rebalance the gut microbiome after exposure to antibiotics | |
US20050214364A1 (en) | Products and methods for treating vaginal infections | |
US20240122958A1 (en) | Beta-adrenergic agonist and muscarinic antagonist compositions and methods of using | |
US20230000901A1 (en) | Method for preventing or treating gastrointestinal distress in humans using mastic gum compositions | |
WO2022091023A1 (en) | Combination of active ingredients, compositions containing it and their use to sustain and strengthen the immune system | |
Isai | Remission in a Patient with Crohn's Disease Treated by Sairei-to and Perilla Oil | |
Plawiuk et al. | Application of Differentiated Osteotropic Therapy in Complex Treatment Program of Generalized Periodontitis in Patients with Concomitant Osteoporosis: Assessment of its Effectiveness | |
US20190255131A1 (en) | A composition comprising an extract of irvingia gabonensis and strains of bifidobacteria for regulating and reducing body weight |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22961182 Country of ref document: EP Kind code of ref document: A1 |